Liver X receptor: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (13 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size=' | <StructureSection load='' size='350' side='right' caption='Human liver X receptor β ligand binding domain (deepskyblue) complex with retinoic X receptor β (green) and modulator (PDB code [[5kya]])' scene='77/776388/Cv/1'> | ||
== Function == | == Function == | ||
'''Liver X | '''Liver X receptors''' (LXR) are ligand-activated transcription factors of the nuclear receptor family. There are two LXR isoforms α and β which form heterodimers with retinoic X receptor upon activation and bind to the LXR response element found in the promoter region of the target genes<ref>PMID:19258656</ref>. LXR is a lipogenic transcription factor<ref>PMID:17107947</ref>. LXRs modulate the expression of genes in cholesterol and lipid metabolism in response to changes in cellular cholesterol status. | ||
*'''Liver X receptor alpha''' has a role in regulating innate immunity at the genomic level. | |||
*'''Liver X receptor beta''' is an important transcription factor promoting the survival of single-positive thymocytes<ref>PMID:32963358</ref>. | |||
See also [[Intracellular receptors]] | |||
== Disease == | == Disease == | ||
| Line 16: | Line 21: | ||
== Structural highlights == | == Structural highlights == | ||
LXR modulator binds to the LXR in the LXR/retinoic X receptor β heterodimer in a hydrophobic pocket<ref>PMID:27599745</ref>. | <scene name='77/776388/Cv/2'>Human liver X receptor β ligand binding domain complex with retinoic X receptor β and modulator</scene>. LXR <scene name='77/776388/Cv/4'>modulator binds to the LXR</scene> in the LXR/retinoic X receptor β heterodimer in a hydrophobic <scene name='77/776388/Cv/5'>pocket</scene><ref>PMID:27599745</ref>. | ||
</StructureSection> | </StructureSection> | ||
== 3D Structures of liver X | == 3D Structures of liver X receptor == | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| Line 25: | Line 30: | ||
* Liver X receptor α | * Liver X receptor α | ||
**[[5avl]], [[5avl]], [[5hjs]], [[3ipq]], [[3ips]], [[3ipu]] – hLXR LBD + NCOA-1 peptide + agonist - human<br /> | |||
**[[1uhl]] – hLXR LBD + retinoic X receptor β + NCOA-2 <br /> | |||
**[[2acl]] – mLXR + retinoic X receptor α + agonist – mouse <br /> | **[[2acl]] – mLXR + retinoic X receptor α + agonist – mouse <br /> | ||
* Liver X receptor β | * Liver X receptor β | ||
**[[1upv]], [[1upw]], [[5jy3]], [[3kfc]], [[4rak]] – hLXR LBD + agonist – | **[[1upv]], [[1upw]], [[5jy3]], [[3kfc]], [[4rak]], [[6s4n]], [[6s4t]], [[6s4u]], [[6s5k]] – hLXR LBD + agonist<br /> | ||
**[[6k9g]], [[6k9h]], [[6k9m]] – hLXR LBD (mutant) + agonist <br /> | |||
**[[1pq6]], [[1pqc]], [[1pq9]] – hLXR LBD + ligand<br /> | **[[1pq6]], [[1pqc]], [[1pq9]] – hLXR LBD + ligand<br /> | ||
**[[6jio]] – hLXR LBD (mutant) + ligand<br /> | |||
**[[5i4v]] – hLXR LBD + retinoic X receptor β + agonist <br /> | **[[5i4v]] – hLXR LBD + retinoic X receptor β + agonist <br /> | ||
**[[5kyj]], [[5kya]] – hLXR LBD + retinoic X receptor β + modulator <br /> | **[[5kyj]], [[5kya]] – hLXR LBD + retinoic X receptor β + modulator <br /> | ||
| Line 38: | Line 45: | ||
**[[5hjp]] – hLXR LBD + retinoic X receptor β + agonist<br /> | **[[5hjp]] – hLXR LBD + retinoic X receptor β + agonist<br /> | ||
**[[4nqa]] – hLXR LBD + retinoic X receptor β + NCOA-2 peptide + DNA <br /> | **[[4nqa]] – hLXR LBD + retinoic X receptor β + NCOA-2 peptide + DNA <br /> | ||
**[[4dk7]], [[4dk8]] – hLXR LBD + NCOA-1 peptide + agonist<br /> | **[[4dk7]], [[4dk8]], [[5avi]] – hLXR LBD + NCOA-1 peptide + agonist<br /> | ||
**[[1p8d]] – hLXR LBD + NCOA-1 peptide + cholesterol derivative<br /> | **[[1p8d]] – hLXR LBD + NCOA-1 peptide + cholesterol derivative<br /> | ||
**[[3l0e]] – hLXR LBD + NCOA-2 peptide + inhibitor<br /> | |||
}} | }} | ||
== References == | == References == | ||
Latest revision as of 13:11, 10 July 2024
FunctionLiver X receptors (LXR) are ligand-activated transcription factors of the nuclear receptor family. There are two LXR isoforms α and β which form heterodimers with retinoic X receptor upon activation and bind to the LXR response element found in the promoter region of the target genes[1]. LXR is a lipogenic transcription factor[2]. LXRs modulate the expression of genes in cholesterol and lipid metabolism in response to changes in cellular cholesterol status.
See also Intracellular receptors DiseaseTreatment of mice demonstrating Wilson disease with LXR agonist reduced disease manifestations without worsening neurological symptoms associated with the conventional therapy based on copper chelation[4]. RelevanceLXRs have emerged as promising drug targets for anti-atherosclerotic therapies[5]. Structural highlights. LXR in the LXR/retinoic X receptor β heterodimer in a hydrophobic [6]. |
| ||||||||||
3D Structures of liver X receptor3D Structures of liver X receptor
Updated on 10-July-2024
ReferencesReferences
- ↑ Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol. 2008 Dec;59 Suppl 7:31-55. PMID:19258656
- ↑ Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007 Jan 5;282(1):743-51. doi: 10.1074/jbc.M605023200. Epub 2006 Nov, 14. PMID:17107947 doi:http://dx.doi.org/10.1074/jbc.M605023200
- ↑ Huang H, Wu X, Meng D, Feng Y, Zhou L, Liu Z, Tang S, Li X, Cao Y, He H, Xie Z, Zhang J, Chen Y, Zhao T, Wu Y, Zhou X. Liver X receptor β is required for the survival of single-positive thymocytes by regulating IL-7Rα expression. Cell Mol Immunol. 2021 Aug;18(8):1969-1980. PMID:32963358 doi:10.1038/s41423-020-00546-y
- ↑ Hamilton JP, Koganti L, Muchenditsi A, Pendyala VS, Huso D, Hankin J, Murphy RC, Huster D, Merle U, Mangels C, Yang N, Potter JJ, Mezey E, Lutsenko S. Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-) (Wilson disease) mice. Hepatology. 2016 Jun;63(6):1828-41. doi: 10.1002/hep.28406. Epub 2016 Feb 22. PMID:26679751 doi:http://dx.doi.org/10.1002/hep.28406
- ↑ Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. Prog Lipid Res. 2010 Oct;49(4):343-52. doi: 10.1016/j.plipres.2010.03.002. Epub, 2010 Apr 2. PMID:20363253 doi:http://dx.doi.org/10.1016/j.plipres.2010.03.002
- ↑ Tice CM, Noto PB, Fan KY, Zhao W, Lotesta SD, Dong C, Marcus AP, Zheng YJ, Chen G, Wu Z, Van Orden R, Zhou J, Bukhtiyarov Y, Zhao Y, Lipinski K, Howard L, Guo J, Kandpal G, Meng S, Hardy A, Krosky P, Gregg RE, Leftheris K, McKeever BM, Singh SB, Lala D, McGeehan GM, Zhuang L, Claremon DA. Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core. Bioorg Med Chem Lett. 2016 Aug 29. pii: S0960-894X(16)30921-0. doi:, 10.1016/j.bmcl.2016.08.089. PMID:27599745 doi:http://dx.doi.org/10.1016/j.bmcl.2016.08.089